SC 13G: Reneo Pharmaceuticals, Inc.

Ticker: OKUR · Form: SC 13G · Filed: Sep 26, 2024 · CIK: 1637715

Sentiment: neutral

Topics: sc-13g

AI Summary

SC 13G filing by Reneo Pharmaceuticals, Inc..

Risk Assessment

Risk Level: low

Filing Stats: 1,571 words · 6 min read · ~5 pages · Grade level 11.1 · Accepted 2024-09-26 16:00:22

Key Financial Figures

Filing Documents

(a). Name of Issuer

Item 1(a). Name of Issuer: Reneo Pharmaceuticals, Inc., a Delaware corporation

(b). Address of Issuer’s Principal Executive Offices

Item 1(b). Address of Issuer’s Principal Executive Offices: 18575 Jamboree Road, Suite 275-S, Irvine, CA 92612

(a). Name of Person Filing

Item 2(a). Name of Person Filing: This Statement on Schedule 13G (this “Statement”) is filed by Tang Capital Partners, LP (“Tang Capital Partners”); Tang Capital Management, LLC, the general partner of Tang Capital Partners (“Tang Capital Management”); Kevin Tang, the manager of Tang Capital Management; and Concentra Biosciences, LLC, an affiliate of Tang Capital Partners, LP (“Concentra”).

(b). Address of Principal Business Office

Item 2(b). Address of Principal Business Office or, if none, Residence: 4747 Executive Drive, Suite 210, San Diego, CA 92121

(c). Citizenship

Item 2(c). Citizenship: Tang Capital Partners is a Delaware limited partnership. Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen. Concentra is a Delaware limited liability company.

(d). Title of Class of Securities

Item 2(d). Title of Class of Securities: Common Stock, par value $0.001 per share

(e). CUSIP Number 75974E103

Item 2(e). CUSIP Number 75974E103

Not applicable

Item 3. Not applicable.

Ownership

Item 4. Ownership. (a) Amount Beneficially Owned: Tang Capital Partners. Tang Capital Partners beneficially owns 2,946,260 of the Issuer’s Common Stock. Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang. Tang Capital Management. Tang Capital Management beneficially owns 2,946,260 of the Issuer’s Common Stock. Page 6 of 9 pages Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners and Kevin Tang. Kevin Tang. Kevin Tang beneficially owns 2,946,260 of the Issuer’s Common Stock. Kevin Tang shares voting and dispositive power over such shares with Tang Capital Partners and Tang Capital Management. The percentages used herein are based on 33,428,808 shares of Common Stock outstanding as of August 9, 2024, as set forth in the Issuer’s Quarterly Report filed on Form 10-Q that was filed with the Securities and Exchange Commission on August 13, 2024. (b) Percent of Class: Tang Capital Partners 8.8% Tang Capital Management 8.8% Kevin Tang 8.8% Concentra 0.0% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Tang Capital Partners 0 shares Tang Capital Management 0 shares Kevin Tang 0 shares Concentra 0 shares (ii) shared power to vote or to direct the vote: Tang Capital Partners 2,946,260 shares Tang Capital Management 2,946,260 shares Kevin Tang 2,946,260 shares Concentra 0 shares (iii) sole power to dispose or to direct the disposition of: Tang Capital Partners 0 shares Tang Capital Management 0 shares Kevin Tang 0 shares Concentra 0 shares (iv) shared power to dispose or to direct the disposition of: Tang Capital Partners 2,946,260 shares Tang Capital Management 2,946,260 shares Kevin Tang 2,946,260 shares Concentra 0 shares Page 7 of 9 pages

Ownership of Five Percent or Less of a Class

Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ¨

Ownership of More than Five Percent on Behalf of Another Person

Item 6. Ownership of More than Five Percent on Behalf of Another Person. Not applicable

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company. Not applicable.

Identification and Classification of Members of the Group

Item 8. Identification and Classification of Members of the Group. Not applicable.

Notice of Dissolution of Group

Item 9. Notice of Dissolution of Group. Not applicable.

Certification

Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Page 8 of 9 pages Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: September 26, 2024 TANG CAPITAL PARTNERS, LP By: Tang Capital Management, LLC, its General Partner By: /s/ Kevin Tang Kevin Tang, Manager TANG CAPITAL MANAGEMENT, LLC By: /s/ Kevin Tang Kevin Tang, Manager /s/ Kevin Tang Kevin Tang CONCENTRA BIOSCIENCES, LLC By: /s/ Kevin Tang Kevin Tang, Chief Executive Officer Page 9 of 9 Pages

View Full Filing

View this SC 13G filing on SEC EDGAR

View on Read The Filing